Press Releases
Morphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American Association for Cancer Research (AACR) Annual Meeting
April 12, 2021
Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering
March 2, 2021
Morphic Therapeutic Announces Proposed Public Offering
March 1, 2021
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
March 1, 2021
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2020
March 1, 2021
Morphic Therapeutic to Host Analyst and Investor Call on March 1, 2021
February 22, 2021
Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference
February 16, 2021
Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program
January 5, 2021